CA3204823A1 - Prmts inhibitors - Google Patents

Prmts inhibitors

Info

Publication number
CA3204823A1
CA3204823A1 CA3204823A CA3204823A CA3204823A1 CA 3204823 A1 CA3204823 A1 CA 3204823A1 CA 3204823 A CA3204823 A CA 3204823A CA 3204823 A CA3204823 A CA 3204823A CA 3204823 A1 CA3204823 A1 CA 3204823A1
Authority
CA
Canada
Prior art keywords
amino
dihydrofuro
methanone
quinolin
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3204823A
Other languages
English (en)
French (fr)
Inventor
Shon Booker
Matthew Paul Bourbeau
John R. Butler
Sanne Omholt Schroder GLAD
Brian Alan Lanman
Patricia Lopez
Francesco Manoni
Liping H. Pettus
Ian SARVARY
Nuria A. Tamayo
Mikkel VESTERGAARD
Nicholas Anthony WEIRES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3204823A1 publication Critical patent/CA3204823A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/16—Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3204823A 2020-12-16 2021-12-15 Prmts inhibitors Pending CA3204823A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063126416P 2020-12-16 2020-12-16
US63/126,416 2020-12-16
PCT/US2021/063540 WO2022132914A1 (en) 2020-12-16 2021-12-15 Prmts inhibitors

Publications (1)

Publication Number Publication Date
CA3204823A1 true CA3204823A1 (en) 2022-06-23

Family

ID=79927288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3204823A Pending CA3204823A1 (en) 2020-12-16 2021-12-15 Prmts inhibitors

Country Status (17)

Country Link
US (2) US11845760B2 (https=)
EP (2) EP4263545B1 (https=)
JP (2) JP7487421B2 (https=)
KR (1) KR20230121820A (https=)
AR (1) AR124369A1 (https=)
AU (1) AU2021400942A1 (https=)
CA (1) CA3204823A1 (https=)
CL (1) CL2023001738A1 (https=)
CO (1) CO2023008167A2 (https=)
CR (1) CR20230310A (https=)
IL (1) IL303451A (https=)
JO (1) JOP20230138A1 (https=)
MX (1) MX2023007192A (https=)
PE (1) PE20231295A1 (https=)
TW (1) TW202233183A (https=)
UY (1) UY39565A (https=)
WO (1) WO2022132914A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11077101B1 (en) 2018-07-18 2021-08-03 Tango Therapeutics, Inc. Compounds and methods of use
WO2021086879A1 (en) 2019-10-28 2021-05-06 Tango Therapeutics, Inc. Compounds and methods of use
CN116568677A (zh) 2020-07-31 2023-08-08 探戈医药股份有限公司 可用于治疗mtap缺乏和/或mta累积癌症的哌啶-1-基-n-吡啶-3-基-2-氧代乙酰胺衍生物
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors
TW202319046A (zh) * 2021-08-30 2023-05-16 美商安進公司 用於合成㖠啶衍生物及其中間體之方法
CA3255376A1 (en) * 2022-04-08 2023-10-12 Amgen Inc. CANCER TREATMENTS USING MTA-COOPERATED PRMT5 INHIBITORS
WO2024002263A1 (zh) * 2022-06-30 2024-01-04 南京明德新药研发有限公司 氨基取代的杂芳基衍生物及其应用
AU2023296592A1 (en) * 2022-07-01 2025-01-30 Cytosinlab Therapeutics Co., Ltd. Class of prmt5 inhibitors and use thereof
CN119013274A (zh) * 2022-07-26 2024-11-22 上海和誉生物医药科技有限公司 一种prmt5抑制剂及其制备方法和药学上的应用
AU2023319559B2 (en) * 2022-08-03 2026-04-16 Abbisko Therapeutics Co., Ltd. Nitrogen-containing fused three ring prmt5 inhibitor, and preparation method therefor and pharmaceutical use thereof
CN119730853A (zh) 2022-08-15 2025-03-28 阿斯利康(瑞典)有限公司 用于治疗癌症的mta协同prmt5抑制剂
JP2025529831A (ja) * 2022-08-18 2025-09-09 メッドシャイン ディスカバリー インコーポレイテッド アミド含有複素環誘導体とその使用
CN117658980A (zh) * 2022-09-08 2024-03-08 郑州同源康医药有限公司 双环类prmt5抑制剂
EP4588920A4 (en) * 2022-09-26 2026-01-28 Shanghai Apeiron Therapeutics Company Ltd NEW PRMT5 INHIBITOR AND ITS USE
IL319814A (en) * 2022-09-26 2025-05-01 Shanghai Apeiron Therapeutics Company Ltd A novel inhibitor of protein arginine methyltransferase 5 and its use
CN115677708B (zh) * 2022-10-19 2024-11-29 深圳万知达企业管理有限公司 一种吡咯并喹喔啉的制备方法
TW202440126A (zh) * 2022-11-30 2024-10-16 美商安進公司 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療
KR20250119589A (ko) * 2022-12-05 2025-08-07 암젠 인크 나프티리딘 화합물의 고체 형태
WO2024131901A1 (zh) * 2022-12-23 2024-06-27 深圳微芯生物科技股份有限公司 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用
CN116332856A (zh) * 2023-01-04 2023-06-27 荟达医药科技(上海)有限公司 一种4-哒嗪甲醇的合成方法
JP2026504889A (ja) 2023-01-18 2026-02-10 アンテンジーン・ディスカバリー・リミテッド Ｐｒｍｔ５阻害化合物およびその使用
WO2024170488A1 (en) 2023-02-13 2024-08-22 Astrazeneca Ab Prmt5 inhibitor for use in cancer therapy
CN120769934A (zh) * 2023-02-28 2025-10-10 美国安进公司 用于合成萘啶衍生物及其中间体的方法
CN121241054A (zh) * 2023-04-14 2025-12-30 北京双鹤润创科技有限公司 氮杂环羰基稠环衍生物及其用途
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
EP4700025A1 (en) 2023-04-23 2026-02-25 Suzhou Genhouse Bio Co., Ltd. Amide compound, pharmaceutical composition comprising same, and use thereof
CN121358731A (zh) * 2023-05-17 2026-01-16 四川科伦博泰生物医药股份有限公司 三并环酰胺化合物、包含其的药物组合物及其制备方法和用途
US11845749B1 (en) 2023-07-13 2023-12-19 King Faisal University Substituted pyrido[4′,3′:5,6]pyrazino[1,2-a]indoles as anticancer agents
WO2025016323A1 (zh) 2023-07-14 2025-01-23 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
CN120943832A (zh) 2023-08-02 2025-11-14 成都微芯药业有限公司 杂环炔基取代的酰胺衍生物、其制备方法及其应用
AU2024319888A1 (en) 2023-08-09 2026-02-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Heteroaryl compound, preparation method therefor, and use thereof in medicine
CN121127472A (zh) 2023-08-18 2025-12-12 江苏亚虹医药科技股份有限公司 蛋白质精氨酸酶甲基转移酶-5抑制剂及其医药用途
AU2024356380A1 (en) * 2023-10-06 2026-04-02 Amgen Inc. Cancer treatments using mta-cooperative prmt5 inhibitors
WO2025077856A1 (en) * 2023-10-12 2025-04-17 Beijing Double-Crane Runchuang Technology Co., Ltd. Tricyclic-carbonyl-nitrogen heterocyclic derivatives and use thereof
US20250154172A1 (en) * 2023-11-03 2025-05-15 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
WO2025166215A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Triheterocyclic guanidino compounds as prmt5 inhibitors
WO2025166229A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic amidino compounds as prmt5 inhibitors
WO2025166274A1 (en) * 2024-02-02 2025-08-07 Ideaya Biosciences, Inc. Tricyclic guanidino compounds as prmt5 inhibitors
WO2025190395A2 (en) * 2024-03-14 2025-09-18 Pharmaengine, Inc. Mta-cooperative prmt5 inhibitor
WO2025215153A1 (en) * 2024-04-10 2025-10-16 Ryvu Therapeutics S.A. Prmt5 inhibitors
WO2025257104A1 (en) 2024-06-10 2025-12-18 Sandvik Mining And Construction Tools Ab Diamond and cemented carbide composite material
WO2025265110A1 (en) 2024-06-21 2025-12-26 Amgen Inc. Oral pharmaceutical compositions comprising a naphthyridine compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106573932B (zh) 2014-08-22 2019-07-30 默克专利股份公司 吲唑类
PL3665179T3 (pl) 2017-08-09 2021-11-29 Prelude Therapeutics, Incorporated Selektywne inhibitory metylotransferazy argininowej białek 5 (prmt5)
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833669A4 (en) * 2018-08-07 2022-05-11 Merck Sharp & Dohme Corp. PRMT5 INHIBITORS
JP7787819B2 (ja) * 2020-02-12 2025-12-17 アムジェン インコーポレイテッド 新規ｐｒｍｔ５阻害剤
AU2021400942A1 (en) * 2020-12-16 2023-07-06 Amgen Inc. PRMT5 inhibitors

Also Published As

Publication number Publication date
EP4263545A1 (en) 2023-10-25
US20220194955A1 (en) 2022-06-23
AU2021400942A9 (en) 2024-10-24
US11845760B2 (en) 2023-12-19
TW202233183A (zh) 2022-09-01
CO2023008167A2 (es) 2023-07-21
IL303451A (en) 2023-08-01
UY39565A (es) 2022-06-30
KR20230121820A (ko) 2023-08-21
JP2023550530A (ja) 2023-12-01
CN116888120A (zh) 2023-10-13
EP4732837A2 (en) 2026-04-29
AR124369A1 (es) 2023-03-22
CL2023001738A1 (es) 2023-11-17
US20240092794A1 (en) 2024-03-21
PE20231295A1 (es) 2023-08-22
AU2021400942A1 (en) 2023-07-06
JP2024102236A (ja) 2024-07-30
CR20230310A (es) 2023-09-01
JP7487421B2 (ja) 2024-05-20
JOP20230138A1 (ar) 2023-06-14
MX2023007192A (es) 2023-07-03
WO2022132914A1 (en) 2022-06-23
EP4263545B1 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
CA3204823A1 (en) Prmts inhibitors
TWI766261B (zh) 蛋白質酪胺酸磷酸酶抑制劑
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
AU2019246753B2 (en) Novel compounds and compositions for inhibition of FASN
CA3042960C (en) Fgfr4 inhibitor, preparation method therefor and pharmaceutical use thereof
EP4288435A1 (en) Tricyclic-amido-bicyclic prmt5 inhibitors
AU2017395023B2 (en) Compounds and methods for CDK8 modulation and indications therefor
WO2022115377A1 (en) Tricyclic carboxamide derivatives as prmt5 inhibitors
CA3170321A1 (en) Novel prmt5 inhibitors
KR20160086930A (ko) 피롤로피롤론 유도체 및 bet 억제제로서의 그의 용도
AU2021289169B2 (en) Spiro compounds as melanocortin 4 receptor antagonists and uses thereof
KR20230104782A (ko) Bcr-abl 티로신 키나제 억제용 7-아자인돌 화합물
JP2019001715A (ja) 三環性化合物
JP2016124810A (ja) 新規縮合ピラゾール誘導体およびその医薬用途
JP6280130B2 (ja) キナーゼ活性のモジュレーターとしての新規イミダゾール−ピペリジニル誘導体
CN116888120B (zh) Prmt5抑制剂
EA048318B1 (ru) Ингибиторы prmt5
HK40091563B (zh) 嘧啶酮类化合物及其用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241206

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241206

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241206

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20241220

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20241220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241220

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250103

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250103

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250103

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20250507

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250523

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251124

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251124

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20260119